Abera has together with it’s collaborators received funding for the PNEUMONAV project. PNEUMONAV will develop a novel intranasal prototype vaccine against pneumococcal infections, which will consist of Outer Membrane Vesicles (OMVs), displaying fragments of novel conserved protein antigens. These antigens will warrant universal protection against all pneumococcal serotypes and can be delivered via intranasal administration. If successful, this next-generation vaccine will be able to decrease the incidence of pneumococcal diseases worldwide. The total granted sum for the project is 2,4 MEUR.